Asset Details
Do you wish to reserve the book?
Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System
Do you wish to request the book?
Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System
2020
Overview
A major obstacle to nanodrugs-mediated cancer therapy is their rapid uptake by the reticuloendothelial system that decreases the systemic exposure of the nanodrugs to tumors and also increases toxicities. Intralipid has been shown to reduce nano-oxaliplatin-mediated toxicity while improving bioavailability. Here, we have found that Intralipid reduces the cytotoxicity of paclitaxel for human monocytic cells, but not for breast, lung, or pancreatic cancer cells. Intralipid also promotes the polarization of macrophages to the anti-cancer M1-like phenotype. Using a xenograft breast cancer mouse model, we have found that Intralipid pre-treatment significantly increases the amount of paclitaxel reaching the tumor and promotes tumor apoptosis. The combination of Intralipid with half the standard clinical dose of Abraxane reduces the tumor growth rate as effectively as the standard clinical dose. Our findings suggest that pre-treatment of Intralipid has the potential to be a powerful agent to enhance the tumor cytotoxic effects of Abraxane and to reduce its off-target toxicities.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ 631/250
/ Albumin-Bound Paclitaxel - pharmacology
/ Animals
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - immunology
/ Breast Neoplasms - pathology
/ Cancer
/ Cell Proliferation - drug effects
/ Female
/ Humanities and Social Sciences
/ Humans
/ Immunity, Innate - drug effects
/ Mice
/ Phospholipids - pharmacology
/ Science
/ Tumors
